First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.
|Videos|September 24, 2011
A Paradigm Shift in the Treatment of Endometrial Cancer
Author(s)Don S. Dizon, MD
Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.
Advertisement
Don Dizon, MD, Brown University, discusses the paradigm shift in the treatment of endometrial cancer with the use of medical therapy, including chemotherapy with biologics, mTOR inhibitors combined with chemotherapy, and targeted therapies.
Advertisement
Related to this article
Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
2
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
3
Iza-Bren Plus Pembrolizumab Shows Activity in Recurrent or Metastatic HNSCC
4
A Pilot Trial of N-803: Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
5